Lunit Completes Acquisition of Volpara Health Read more

AI-Powered PD-L1 Quantification for Immunotherapy


benefits

Close to the
Ground Truth

Trained with 1M+ cell annotations by 150+ pathologists worldwide, Lunit SCOPE PD-L1 generates analysis results that are close to the ground truth.

Reduced discrepancy

By generating objective results, Lunit SCOPE PD-L1 reduces interpretation discrepancy between pathologists.

Patient Enrichment

Based on an accuracy of 96%, Lunit SCOPE PD-L1 finds 50% more patients eligible for immunotherapy compared to human-classified PD-L1(-) patient group.

* Lunit SCOPE PD-L1 is currently applicable to NSCLC (non-small cell lung cancer) only.

Features

Detection

Detects tumor cell PD-L1 +/- and inflammatory cell PD-L1 +/- from whole slide images

Quantification

Calculates PD-L1 positive score including TPS (Tumor Proportion Score) and CPS (Combined Positive Score; to be provided).

AI - TPS
Number of All Tumor Cells 471,861 (100.0%)
Number of PD-L1 Positive Tumor Cells 441,190 (93.5%)
Number of PD-L1 Negative Tumor Cells 30,199 (6.4%)

AI Score and Report

Provides AI analysis results including PD-L1 TPS score and map within a report.

USER-READ
Number of All Tumor Cells 427,094
Number of PD-L1 Positive Tumor Cells 414,678
Number of PD-L1 Negative Tumor Cells 12,416

*User-read is computed by user defined PD-L1 positive and negative cells within user drawn ROI.

How it works

Publications featuring
Lunit SCOPE PD-L1

No Data

Lunit SCOPE IO

AI-Powered Biomarker for Immuno-Oncology

Publication

Making data-driven medicine a reality